Abstract 6014
Background
The impact of FLT3ITDmut on post-transplant outcome of adult AML remains controversial. A decreased leukemia-free survival (LFS) after allogeneic hematopoietic stem cell transplantation (HSCT) for adult AML in complete remission (CR) was observed in EBMT analysis but not CIBMTR. The impact of FLT3ITDmut on AML patients in later disease stage, as well as the influence of concurrent NPM1 mutation on post-transplant outcome, is less well studied.
Methods
In this study, only adults aged ≥ 18 years with a diagnosis of de novo AML who received allogeneic peripheral blood stem cell transplantation and with known FLT3ITD and NPM1 status in the registry were included. Kaplan-Meier estimates were used to calculate LFS and overall survival (OS). Multivariate analyses for LFS and OS were performed using Cox proportional hazards model.
Results
For patients who received transplant in CR1, the 2 year LFS, OS, and relapse incidence (RI) were 33.1%, 48.7%, and 56%, respectively, for patients of FLT3ITDmutNPM1wt, which are much inferior to patients of FLT3ITDmutNPM1mut (74.3%, 77.8%, and 25.7%, respectively) and patients of FLT3ITDwt (53.5%, 71%, and 37.3%, respectively). In multivariate analysis, patients of FLT3ITDmutNPM1wt, but not patients of FLT3ITDmutNPM1mut, were associated with significant poor LFS (HR 2.672, p = 0.007) and OS (HR 2.439, p = 0.038) compared with patients of FLT3ITDwt. For patients who received transplant after CR1, FLT3ITDmut was associated with significant poor LFS (HR 1.775, p = 0.013) and OS (HR 1.716, p = 0.028) compared with patients of FLT3ITDwt. NPM1 mutation dose not influence the outcome.
Conclusions
For patients in CR1, the impact of FLT3ITD is markedly modified by NPM1 status. The post-transplant outcome remains poor for patients of FLT3ITDmutNPM1wt and highlights the need for a novel approach (such as maintenance FLT3ITD inhibitor after transplant). For patients after CR1, the post-transplant outcome is very poor for patients of FLT3ITDmut and is independent of NPM1 status.
Clinical trial identification
Editorial acknowledgement
The author thanks all the centers participating in the TBMTR. The report is on behalf of the Taiwan society of blood and bone marrow transplantation.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1757 - Development of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumor treatment
Presenter: Li-Shuang Ai
Session: Poster Display session 1
Resources:
Abstract
4156 - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells.
Presenter: Nunzia Matrone
Session: Poster Display session 1
Resources:
Abstract
2949 - EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models
Presenter: Nicola Gaynor
Session: Poster Display session 1
Resources:
Abstract
4270 - The impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer
Presenter: Maysa Al-natsheh
Session: Poster Display session 1
Resources:
Abstract
1568 - Application of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures
Presenter: Vilma Petrikaite
Session: Poster Display session 1
Resources:
Abstract
5400 - Tr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55
Presenter: Iniobong Charles
Session: Poster Display session 1
Resources:
Abstract
5817 - Functional analysis of tumor infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B
Presenter: Hitomi Kawaji
Session: Poster Display session 1
Resources:
Abstract
2287 - Aberrant glycolysis associates with inflammatory tumor microenvironment and promotes metastasis in triple-negative breast cancer
Presenter: Chengwei Lin
Session: Poster Display session 1
Resources:
Abstract
735 - Anti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer.
Presenter: Fumi Tetsuo
Session: Poster Display session 1
Resources:
Abstract
2105 - The Inhibitory Effect in Oral Squamous Cell Carcinoma Cells by Knocking down Matrix Metalloproteinase 9
Presenter: Xinyan Zhang
Session: Poster Display session 1
Resources:
Abstract